Study M158
Study name | Egami M 2013 |
Title | Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression |
Overall design | The aim of this study was to compare saliva levels of 3-methoxy-4-hydroxyphenylglycol (sMHPG) in patients with major depressive disorder (MDD) to levels in healthy controls and explored whether sMHPG levels in patients with MDD were a predictive marker for antidepressant efficacy. sMHPG levels were compared in 53 patients with MDD (depressed group) and 275 age-matched healthy controls (control group). Patients' depressive symptoms were assessed by the 17-item Hamilton Rating Scale for Depression at baseline and 4 weeks after treatment with selective serotonin reuptake inhibitors (SSRIs, n = 23) or mirtazapine (n = 30), followed by saliva sampling. Patients with at least a 50% decrease on their HRSD score assessed 4 weeks later were classified as responders; the remaining patients were considered non-responders. sMHPG levels were measured by gas chromatography-mass spectrometry. |
Study Type | Type1; Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 >= 16 |
Sample size | 328 |
Tissue | Peripheral; Saliva; Saliva; |
Platform | MS-based; GC-MS: GC-MS QP-5050A (Shimadzu Scientific Instruments, Kyoto, Japan); |
PMID | |
DOI | |
Citation | Egami M, Imamura Y, Nabeta H, et al. Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression. Hum Psychopharmacol 2013;28(1):7-14. |
Metabolite |
